LSTA:NASDAQ
Lisata Therapeutics, Inc.
1,07 $
arrow_downward
-1,83%(-0,020) 1D
17 նոյ, 12:05:42 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
1,08 $
High
1,10 $
Low
1,00 $
Mkt. cap
11,56 մլն
Avg. vol.
135,12 հզր
Volume
230,10 հզր
52-wk high
5,06 $
52-wk low
0,96 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
Open
1,08 $
High
1,10 $
Low
1,00 $
Mkt. cap
11,56 մլն
Avg. vol.
135,12 հզր
Volume
230,10 հզր
52-wk high
5,06 $
52-wk low
0,96 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
News stories
From web sources and news partners
TradingView
·
1 ժամ առաջ
QUICK SPARK: Walmart Stock Has Best 2-Month Run Against S&P 500 Since 1975
MarketWatch
·
36 րոպե առաջ
Why Salesforce’s stock is leading S&P 500 decliners amid tech jitters
Benzinga
·
1 ժամ առաջ
S&P 500 Down 1%; Disney Posts Upbeat Earnings
BigGo Finance
·
1 ժամ առաջ
Netflix Shares Trade Below S&P 500 Multiple After 35% Slide as Analysts See Upside
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, Նյու Ջերսի, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitelisata.com